Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 366

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study

Open access
Subbiah, Vivek, Hu, Mimi I, Wirth, Lori J, Schuler, Martin, Mansfield, Aaron S, Curigliano, Giuseppe, Brose, Marcia S, Zhu, Viola W, Leboulleux, Sophie, Bowles, Daniel W, Baik, Christina S, Adkins, Douglas, Keam, Bhumsuk, Matos, Ignacio, Garralda, Elena, Gainor, Justin F, Lopes, Gilberto, Lin, Chia-Chi, Godbert, Yann, Sarker, Debashis, Miller, Stephen G, Clifford, Corinne, Zhang, Hui, Turner, Christopher D, Taylor, Matthew H·2021·The Lancet Diabetes & Endocrinology

Abstract

Background: Oncogenic alterations in RET represent important therapeutic targets in thyroid cancer. Pralsetinib is a highly potent, selective RET inhibitor. Methods: ARROW, a phase 1/2, open-label study conducted in 13 countries across 84 sites, enrolled patients with RET-altered locally advanced/metastatic solid tumours, including RET-mutant medullary thyroid and RET fusion–positive thyroid cancers. Phase 2 primary endpoints, assessed for patients who received 400 mg once-daily oral pralsetinib, were overall response rate (Response Evaluation Criteria in Solid Tumours version 1·1; blinded independent central review) and safety. Tumour response was assessed for patients with RET-mutant medullary thyroid cancer who had received prior cabozantinib and/or vandetanib or were ineligible for standard therapy and patients with previously treated RET fusion–positive thyroid cancer; safety was assessed for all patients with RET-altered thyroid cancer. Findings: Between Mar 17, 2017, and May 22, 2020, 122 patients with RET-mutant medullary and 20 with RET fusion–positive thyroid cancers were enrolled. Among patients with baseline measurable disease who received pralsetinib by July 11, 2019 (enrolment cut-off), response rates were 71% (95% confidence interval [CI] 48–89; n=15/21) in patients with treatment-naïve RET-mutant medullary thyroid cancer and 60% (95% CI 46–73; n=33/55) in patients who previously received cabozantinib and/or vandetanib, and 89% (95% CI 52–100; n=8/9) in patients with RET fusion–positive thyroid cancer (all confirmed for each group). Common (≥10%) grade ≥3 treatment-related adverse events among patients with RET-altered thyroid cancer enrolled by May 22, 2020 (n=142) were hypertension (17%), neutropenia (13%), lymphopenia (12%), and anaemia (10%); 4% discontinued due to treatment-related events. Interpretation: Pralsetinib is a new, well-tolerated, potent once-daily oral treatment option for patients with RET-altered thyroid cancer. Funding: Blueprint Medicines Corporation, Cambridge, Massachusetts, USA

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s2213-8587(21)00120-0

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 23 references

Cited by

See all 366

Metadata

Authors
Subbiah, V., Hu, M. I., Wirth, L. J., Schuler, M., Mansfield, A. S., Curigliano, G., Brose, M. S., Zhu, V. W., Leboulleux, S., Bowles, D. W., Baik, C. S., Adkins, D., Keam, B., Matos, I., Garralda, E., Gainor, J. F., Lopes, G., Lin, C.-C., Godbert, Y., Sarker, D., Miller, S. G., Clifford, C., Zhang, H., Turner, C. D., & Taylor, M. H.
Venue
The Lancet Diabetes & Endocrinology
Publisher
Elsevier BV
Published
2021-08
Volume
9
Issue
8
Pages
491-501
ISSN
2213-8587 (ISSN-L)
OpenAlex
W3166643980
Cited by
366
References
23
FWCI
39.26
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study. https://app.cochat.ai/papers/10.1016/s2213-8587(21)00120-0
The paper
Subbiah, V., Hu, M. I., Wirth, L. J., Schuler, M., Mansfield, A. S., Curigliano, G., Brose, M. S., Zhu, V. W., Leboulleux, S., Bowles, D. W., Baik, C. S., Adkins, D., Keam, B., Matos, I., Garralda, E., Gainor, J. F., Lopes, G., Lin, C.-C., Godbert, Y., . . . Taylor, M. H. (2021). Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(21)00120-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.